Publications / National Research Projects
Experts in small molecule drug development, brain disease therapeutics,
and pharmaceutical R&D
have come together with a shared goal: to develop treatments,
for intractable brain disorders.
NO
Year
Title
Journal
IF (%)
Pipeline
11
2024
Highly potent and selective PPARδ agonist reverses memory deficits in mouse models of Alzheimer's disease
Theranostics
12.4(Top 4.0%)
CV-04
10
2024
"Discovery of the therapeutic potential of PPARδ agonist bearing 1,3,4- thiadiazole in inflammatory disorders"
European Journal of Medicinal Chemistry
6.0(Top 10.4%)
CV-04
9
2024
Discovery and Optimization of a Series of Vinyl Sulfoximine-Based Analogues as Potent Nrf2 Activators for the Treatment of Multiple Sclerosis
Journal of Medicinal Chemistry
6.9 (Top 3.5%)
CV-01
8
2023
Exploration of Tetrahydroisoquinoline- and Benzo[ c]azepine-Based Sphingosine 1-Phosphate Receptor 1 Agonists for the Treatment of Multiple Sclerosis
Journal of Medicinal Chemistry
6.9 (Top 3.5%)
CV-02
7
2023
Optimization and evaluation of pyridinyl vinyl sulfones as Nrf2 activator for the antioxidant and anti-inflammatory effects
European Journal of Medicinal Chemistry
6.0(Top 10.4%)
CV-01
6
2022
Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis
Journal of Medicinal Chemistry
6.9 (Top 3.5%)
CV-02
5
2021
Development and optimization of halogenated vinyl sulfones as Nrf2 activators for the treatment of Parkinson’s disease
European Journal of Medicinal Chemistry
6.0(Top 10.4%)
CV-01
4
2020
A novel chalcone derivative as Nrf2 activator attenuates learning and memory impairment in a scopolamine-induced mouse model
European Journal of Medicinal Chemistry
6.0(Top 10.4%)
CV-01
3
2019
Optimization of Vinyl Sulfone Derivatives as Potent Nuclear Factor Erythroid 2‑Related Factor 2 (Nrf2) Activators for Parkinson’s Disease Therapy
Journal of Medicinal Chemistry
6.9(Top 3.5%)
CV-01
2
2019
Antioxidant, Anti-inflammatory, and Neuroprotective Effects of Novel Vinyl Sulfonate Compounds as Nrf2 Activator
ACS Medicinal Chemistry Letters
3.5
CV-01
1
2014
Discovery of Vinyl Sulfones as a Novel Class of Neuroprotective Agents toward Parkinson’s Disease Therapy
Journal of Medicinal Chemistry
6.9(Top 3.5%)
CV-01
NO . 11
2024
Highly potent and selective PPARδ agonist reverses memory deficits in mouse models of Alzheimer's disease
Theranostics
12.4(상위4.0%)
CV-04
NO .10
2024
"Discovery of the therapeutic potential of PPARδ agonist bearing 1,3,4- thiadiazole in inflammatory disorders"
European Journal of Medicinal Chemistry
6.0(상위10.4%)
CV-04
NO .9
2024
Discovery and Optimization of a Series of Vinyl Sulfoximine-Based Analogues as Potent Nrf2 Activators for the Treatment of Multiple Sclerosis
Journal of Medicinal Chemistry
6.9 (상위3.5%)
CV-01
NO . 8
2023
Exploration of Tetrahydroisoquinoline- and Benzo[ c]azepine-Based Sphingosine 1-Phosphate Receptor 1 Agonists for the Treatment of Multiple Sclerosis
Journal of Medicinal Chemistry
6.9 (상위3.5%)
CV-02
NO .7
2023
Optimization and evaluation of pyridinyl vinyl sulfones as Nrf2 activator for the antioxidant and anti-inflammatory effects
European Journal of Medicinal Chemistry
6.0(상위10.4%)
CV-01
NO .6
2022
Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis
Journal of Medicinal Chemistry
6.9 (상위3.5%)
CV-02
NO .5
2021
Development and optimization of halogenated vinyl sulfones as Nrf2 activators for the treatment of Parkinson’s disease
European Journal of Medicinal Chemistry
6.0(상위10.4%)
CV-01
NO .4
2020
A novel chalcone derivative as Nrf2 activator attenuates learning and memory impairment in a scopolamine-induced mouse model
European Journal of Medicinal Chemistry
6.0(상위10.4%)
CV-01
NO .3
2019
Optimization of Vinyl Sulfone Derivatives as Potent Nuclear Factor Erythroid 2‑Related Factor 2 (Nrf2) Activators for Parkinson’s Disease Therapy
Journal of Medicinal Chemistry
6.9(상위3.5%)
CV-01
NO .2
2019
Antioxidant, Anti-inflammatory, and Neuroprotective Effects of Novel Vinyl Sulfonate Compounds as Nrf2 Activator
ACS Medicinal Chemistry Letters
3.5
CV-01
NO .1
